QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.106.013797v1 35/8/1418    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waldmeier, F. Articles by Vaidyanathan, S. Search for Related Content PubMed PubMed Citation Articles by Waldmeier, F. Articles by Vaidyanathan, S.

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

Novartis Pharma AG, Basel, Switzerland (F.W., U.G., B.W., L.O., D.S., P.E.); Swiss Pharma Contract Ltd., Allschwil, Switzerland (M.S.); Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (J.V., S.V.); and Novartis Pharma SAS, Rueil-Malmaison, France (G.-J.R.)

Aliskiren (2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-octanamid hemifumarate) is the first in a new class of orally active, nonpeptide direct renin inhibitors developed for the treatment of hypertension. The absorption, distribution, metabolism, and excretion of [¹⁴C]aliskiren were investigated in four healthy male subjects after administration of a single 300-mg oral dose in an aqueous solution. Plasma radioactivity and aliskiren concentration measurements and complete urine and feces collections were made for 168 h postdose. Peak plasma levels of aliskiren (C_max) were achieved between 2 and 5 h postdose. Unchanged aliskiren represented the principal circulating species in plasma, accounting for 81% of total plasma radioactivity (AUC_0–), and indicating very low exposure to metabolites. Terminal half-lives for radioactivity and aliskiren in plasma were 49 h and 44 h, respectively. Dose recovery over 168 h was nearly complete (91.5% of dose); excretion occurred almost completely via the fecal route (90.9%), with only 0.6% recovered in the urine. Unabsorbed drug accounted for a large dose proportion recovered in feces in unchanged form. Based on results from this and from previous studies, the absorbed fraction of aliskiren can be estimated to approximately 5% of dose. The absorbed dose was partly eliminated unchanged via the hepatobiliary route. Oxidized metabolites in excreta accounted for at least 1.3% of the radioactive dose. The major metabolic pathways for aliskiren were O-demethylation at the phenyl-propoxy side chain or 3-methoxy-propoxy group, with further oxidation to the carboxylic acid derivative.

This article has been cited by other articles:

				S. Vaidyanathan, G. Camenisch, H. Schuetz, C. Reynolds, C.-M. Yeh, M.-N. Bizot, H. A. Dieterich, D. Howard, and W. P. Dole Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren J. Clin. Pharmacol., November 1, 2008; 48(11): 1323 - 1338. [Abstract] [Full Text] [PDF]

				H. Krum Role of renin in heart failure and therapeutic potential of direct renin inhibition Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 177 - 180. [PDF]

				M. J. Brown Aliskiren Circulation, August 12, 2008; 118(7): 773 - 784. [Abstract] [Full Text] [PDF]

				D. J. Campbell Interpretation of Plasma Renin Concentration in Patients Receiving Aliskiren Therapy Hypertension, January 1, 2008; 51(1): 15 - 18. [Full Text] [PDF]